US Patent 12,569,474: Scope, Claims, and US Patent Landscape for Once-Daily Oral Anemia Treatment in Chronic Kidney Disease
US Patent 12,569,474 is claim-dense and method-centric. It claims a once-daily oral dosing regimen of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (the patent’s “Compound 1”) for treating anemia secondary to or associated with chronic kidney disease (CKD), with dose options fixed at 150, 300, 450, and 600 mg. The dependent claims then narrow patient subpopulations by CKD setting (pre-dialysis vs dialysis) and CKD stage (3, 4, or 5), with the same discrete dose set carried through.
What is the core claimed invention?
The independent claim (Claim 1) is a tight fit around four elements:
-
Indication/target condition
- “treating anemia secondary to or associated with chronic kidney disease”
-
Route and schedule
- Oral administration
- Once daily dose
-
Active ingredient identity
- “a once daily dose of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, or a pharmaceutically acceptable salt thereof”
- This is the patent’s Compound 1 (as reflected in the claims you provided)
-
Dose range is not open-ended
- “150 mg, 300 mg, 450 mg, or 600 mg of Compound 1”
Independent claim scope in plain terms
A product developer cannot avoid Claim 1 by switching from oral to parenteral, by changing the schedule away from once-daily, by using a different dosing frequency, or by adopting a continuous titration that omits the discrete dose points. Avoiding Claim 1 generally requires changing at least one claim-critical boundary: (a) active ingredient, (b) oral once-daily schedule, (c) indication definition, (d) dose values.
What does Claim 1 cover, and what does it exclude?
Covered
- Any patient with anemia that is secondary to or associated with CKD
- Treated using:
- Oral dosing
- Once daily
- Dose lands exactly on one of:
- 150 mg
- 300 mg
- 450 mg
- 600 mg
- Compound is:
- {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
- or a pharmaceutically acceptable salt of that compound
Excluded by claim language (high-level)
- Non-once-daily regimens (e.g., twice daily, every other day)
- Non-oral administration routes (e.g., IV, SC, intranasal), since Claim 1 requires oral administration
- Dosing schedules that are once daily but use dose levels not among the four fixed amounts
- Indications not framed as anemia secondary to or associated with CKD (even if anemia exists)
How do the dependent claims narrow the scope?
The dependent claims do not broaden Claim 1. They add qualifiers that reduce the class of eligible patients while preserving the same discrete dose set.
Claim set and narrowing effects
| Claim |
Adds qualifier |
Patient subset defined |
Dose constraints |
| 2 |
CKD setting |
Pre-dialysis CKD |
inherits 150/300/450/600 |
| 3-6 |
dose-specific |
pre-dialysis CKD |
single fixed dose each: 150, 300, 450, 600 mg |
| 7 |
CKD setting |
Dialysis patient |
inherits 150/300/450/600 |
| 8-11 |
dose-specific |
dialysis patient |
single fixed dose each: 150, 300, 450, 600 mg |
| 12 |
CKD stage |
Stage 3, 4, or 5 CKD |
inherits 150/300/450/600 |
| 13-16 |
dose-specific |
stage 3/4/5 CKD |
single fixed dose each: 150, 300, 450, 600 mg |
Key legal/technical implication
The dependent-claim structure means the patent asserts infringement coverage across multiple commercial dosing plans that match the listed dose values. A challenger cannot win by arguing that only one patient setting is covered because Claim 1 already spans all CKD settings and simply requires anemia associated with CKD. Dependent claims then tighten to:
- pre-dialysis vs dialysis, and/or
- CKD stage 3/4/5.
What does “pharmaceutically acceptable salt” expand, and where are the practical boundaries?
Claim 1 includes “a pharmaceutically acceptable salt thereof,” which expands the infringement theory beyond the free base/acid form to salt forms. Practically, this captures:
- salt variants of Compound 1 that are used as approved drug substances or that are treated as “pharmaceutically acceptable” in the formulation context.
The claim boundary is not “any derivative.” It is still anchored to the same core compound identity:
- “Compound 1” (as defined by the chemical name) or its pharmaceutically acceptable salts.
What is the scope of dose design-around?
The claim ties infringement to four exact dose values. This creates a dosing design variable that is unusually explicit.
In-scope dose points (Claim 1 and all dependent claims)
- 150 mg
- 300 mg
- 450 mg
- 600 mg
(all as once daily oral doses)
Likely weak spots for infringement arguments (purely from the claim text)
- Once-daily regimens using doses that are not one of the four fixed amounts.
- Regimens with structured titration where the patient spends time at non-listed doses.
However, because dependent claims lock the dose values again for specific subgroups, any launch plan that uses one of these dose points in the claimed patient populations at the once-daily oral schedule is directly implicated.
What is the patent landscape relevance in the US?
Based solely on the claim text you provided, the landscape risk is concentrated in patents that also cover:
- the same compound (Compound 1),
- the anemia indication in CKD,
- and especially the oral once-daily regimen with the fixed dose points.
At the level of “landscape strategy,” US infringement exposure typically clusters into three buckets:
1) Composition-of-matter patents
These cover Compound 1 itself or salt forms. If such patents exist, they usually dominate long-term exclusivity because they cover the molecule regardless of use.
2) Method-of-use (indication) patents
Your claims are method-of-use claims for treating CKD-associated anemia. These can survive even when alternative dosing or administration routes are used, depending on how narrow or broad the claim set is.
3) Regimen and dose-optimization patents
The four discrete doses (150/300/450/600 mg) and “once daily” schedule suggest an optimization claim layer. These can create “dose moat” effects: even when a competitor changes frequency or route, choosing one of the listed dose points can re-enter infringement territory.
Practical read across to business decisions
- If Compound 1 is already near-commercial, landscape blocking is usually driven by whether earlier priority patents cover the compound and whether additional patents claim specific dosing regimens.
- If a competitor intends to launch a product with the same compound, the major commercial risk is whether their intended label dosing matches the four dose points and whether the label claims CKD-associated anemia.
What is the claim strategy signal from the dose matrix?
The claim set is engineered like a coverage matrix:
- Two CKD settings (pre-dialysis and dialysis)
- One CKD stage range (stage 3-5)
- Four dose levels (150, 300, 450, 600 mg)
- Plus a broad independent method claim for CKD-associated anemia regardless of stage or dialysis status.
This structure indicates the patent holder’s expectation that:
- the product may be used across multiple CKD populations; and
- the marketed regimen likely aligns with these fixed doses.
How could a competitor’s US development plan run into this patent?
A typical US product plan that triggers this patent would include all of the following:
- active ingredient is Compound 1 (or a pharmaceutically acceptable salt),
- oral formulation,
- dosing is once daily,
- label indication includes anemia secondary to or associated with CKD,
- and dosage instructions include one or more of the four listed dose strengths (150, 300, 450, 600 mg) in the relevant patient populations.
Even if the label describes one subgroup (e.g., dialysis patients), the broad Claim 1 still covers “anemia secondary to or associated with CKD” in general, while dependent claims cover subgroup-specific dosing.
What are the actionable scope boundaries for freedom-to-operate (FTO)?
From an FTO standpoint, the actionable “yes/no” gates created by this patent are:
-
Compound identity
- Must be exactly Compound 1 (or pharmaceutically acceptable salt), based on the chemical name.
-
Route
-
Schedule
-
Dose strength
- Must be one of 150/300/450/600 mg once daily.
-
Indication framing
- Must treat anemia secondary to or associated with CKD.
-
Patient subgroup
- Even without relying on dependent claims, Claim 1 covers CKD-associated anemia broadly. Dependent claims further support infringement for pre-dialysis, dialysis, and stage 3-5 cohorts when using the dose strengths.
Key Takeaways
- US Patent 12,569,474 is a once-daily oral method-of-treatment patent for CKD-associated anemia using Compound 1 (or its pharmaceutically acceptable salts).
- Claim 1 already covers all CKD-associated anemia patients; dependent claims then narrow to pre-dialysis, dialysis, and CKD stages 3-5 while fixing the same four dose levels.
- The dose strategy is explicit: 150, 300, 450, 600 mg once daily. Those four points are the main commercial infringement landmines.
- Any US development plan using the same compound and aligning dosing and indication language with the claim boundaries faces direct method-of-use risk independent of patient subgroup.
FAQs
1) Does Claim 1 require a specific CKD stage or dialysis status?
No. Claim 1 covers anemia secondary to or associated with CKD generally. Dependent claims specify pre-dialysis, dialysis, and stage 3-5.
2) Is twice-daily dosing covered?
Not by the claims as provided. Claim 1 requires “once daily” oral administration.
3) Does the patent cover salt forms?
Yes. Claim 1 includes “a pharmaceutically acceptable salt thereof.”
4) Are dose levels flexible within the claim?
No. Claim 1 limits once-daily doses to 150, 300, 450, or 600 mg.
5) Which patient populations are explicitly called out?
Dependent claims cover pre-dialysis, dialysis patients, and stage 3, 4, or 5 CKD cohorts.
References
[1] US Patent 12,569,474, claims 1-16 (as provided in the user prompt).
